Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1614 1615 1628
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19353396 | PARTICLE-FORM HYBRID-SCALE FIBER MATRIX | Non-Final OA | Acera Surgical, Inc. |
| 18146973 | MICROARRAY FOR DELIVERY OF THERAPEUTIC AGENT AND METHODS OF USE | Final Rejection | Panther Life Sciences Corporation |
| 18580859 | Reducing the Risk of Infection from Bacteria Present in Skin Pores During Surgery | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18239036 | PATCH GRAFT COMPOSITIONS FOR CELL ENGRAFTMENT | Final Rejection | The University of North Carolina at Chapel Hill |
| 18612755 | MICROSPHERE-BASED DRUG DELIVERY PLATFORM FOR DELIVERY OF IMMUNOTHERAPEUTIC AGENTS | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18695440 | COMPOSITIONS FOR USE | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18695554 | SOLID COMPOSITION FOR DYEING KERATIN | Non-Final OA | KAO CORPORATION |
| 17765926 | MULTI-LAYERED NANOPARTICLE COATED SUBSTRATES FOR DRUG DELIVERY | Final Rejection | The UAB Research Foundation |
| 17610611 | METHOD FOR COATING A MEDICAL DEVICE AND COATED MEDICAL DEVICE | Final Rejection | MEDIZINISCHE HOCHSCHULE HANNOVER |
| 17238882 | HOLLOW CORE GRANULES, PRODUCTS INCORPORATING THE GRANULES, AND METHODS OF PREPARING THE GRANULES | Non-Final OA | Church & Dwight Co., Inc. |
| 18687741 | ODOUR COUNTERACTION | Non-Final OA | GIVAUDAN SA |
| 17871339 | CROSSLINKED PARTICLES | Non-Final OA | The Governing Council of the University of Toronto |
| 18699259 | Composition for Improving Vision | Non-Final OA | ALGAE HEALTH SCIENCES CO., LTD. |
| 18696821 | COSMETIC COMPOSITION COMPRISING EUTECTIC MIXTURE OF VITAMIN C | Non-Final OA | LG HOUSEHOLD & HEALTH CARE LTD. |
| 18617354 | LAYERED PARTICLES AND PROCESSES THEREOF | Non-Final OA | Delphi Scientific, LLC |
| 18608586 | ORALLY DISINTEGRATING NICOTINE TABLET FOR USE UNDER LIP | Non-Final OA | Fertin Pharma A/S |
| 18589995 | INHALABLE DRY POWDER FORMULATIONS COMPRISING ANGIOGENESIS INHIBITORS | Non-Final OA | Lonza Bend Inc. |
| 18685305 | MEDICAL LIQUID COMPOSITION FOR AERIAL ADMINISTRATION | Final Rejection | APE8 S.R.L. |
| 17920163 | APPLICATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION TO PREPARATION OF MEDICINE FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Non-Final OA | JIANGSU KANION PHARMACEUTICAL CO., LTD. |
| 18187898 | POSTERIOR SEGMENT DRUG DELIVERY | Non-Final OA | ForSight Vision4, Inc. |
| 18181205 | GRANULATED PRODUCT AND METHOD FOR PRODUCING SAME | Final Rejection | TOYO SHINYAKU CO., LTD. |
| 18167842 | Pharmaceutical Composition For Preventing And Treating Inflammatory Bowel Disease | Final Rejection | Centre for Chinese Herbal Medicine Drug Development Limited |
| 17626176 | Anti-Microbial Composition and Method of Using Same | Final Rejection | ARXADA, LLC |
| 18345895 | DISINFECTANTS WITH IODINE AND COPPER COMPLEXES FOR BIOFILM ERADICATION AND PREVENTION | Non-Final OA | CLYRA Medical Technologies, Inc. |
| 18216818 | ETHYLCELLULOSE FORMULATIONS AND METHODS OF MAKING SAME | Non-Final OA | DUPONT NUTRITION USA, INC |
| 17417179 | DIFFUSER OF VOLATILE SUBSTANCES BY COMBUSTION | Final Rejection | ZOBELE HOLDING SPA |
| 18295181 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
| 18247774 | INTEGRATED PROCESS FOR THE ECO-SUSTAINABLE PRODUCTION OF HIGH QUALITY EXTRA VIRGIN OLIVE OIL AND MICRONIZED BY PRODUCTS | Non-Final OA | MANNI OIL SOCIETÀ AGRICOLA S.R.L. |
| 17169490 | Compositions and Methods for Regulating Homeostasis of Chondrocytes, Extracellular Matrix, Articular Cartilage, and Phenotype of Arthritis | Non-Final OA | Unigen, Inc. |
| 18040758 | ADDITIVE TO FISH FOOD COMPRISING TWO PLANT EXTRACTS AND A SEAWEED (PALMARIA PALMATA) EXTRACT AS TASTE MASKING AGENT; AND A METHOD TO COMBAT/ELIMINATE INFESTATIONS OF CALIGUS BY STERILIZATION OF FEMALE INDIVIDUALS IN FISH FARMING CENTERS AND MARINE CONCESSIONS | Final Rejection | ACUANATIVA SPA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy